Chirra Martina, Newton Hannah S, Gawali Vaibhavkumar S, Wise-Draper Trisha M, Chimote Ameet A, Conforti Laura
Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Division of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Cancers (Basel). 2022 Jul 22;14(15):3564. doi: 10.3390/cancers14153564.
Competent antitumor immune cells are fundamental for tumor surveillance and combating active cancers. Once established, tumors generate a tumor microenvironment (TME) consisting of complex cellular and metabolic elements that serve to suppress the function of antitumor immune cells. T lymphocytes are key cellular elements of the TME. In this review, we explore the role of ion channels, particularly K channels, in mediating the suppressive effects of the TME on T cells. First, we will review the complex network of ion channels that mediate Ca influx and control effector functions in T cells. Then, we will discuss how multiple features of the TME influence the antitumor capabilities of T cells via ion channels. We will focus on hypoxia, adenosine, and ionic imbalances in the TME, as well as overexpression of programmed cell death ligand 1 by cancer cells that either suppress K channels in T cells and/or benefit from regulating these channels' activity, ultimately shaping the immune response. Finally, we will review some of the cancer treatment implications related to ion channels. A better understanding of the effects of the TME on ion channels in T lymphocytes could promote the development of more effective immunotherapies, especially for resistant solid malignancies.
有功能的抗肿瘤免疫细胞是肿瘤监测和对抗活跃癌症的基础。肿瘤一旦形成,就会产生一个由复杂的细胞和代谢成分组成的肿瘤微环境(TME),这些成分会抑制抗肿瘤免疫细胞的功能。T淋巴细胞是TME的关键细胞成分。在这篇综述中,我们探讨离子通道,特别是钾通道,在介导TME对T细胞的抑制作用中的作用。首先,我们将回顾介导钙离子内流并控制T细胞效应功能的离子通道复杂网络。然后,我们将讨论TME的多个特征如何通过离子通道影响T细胞的抗肿瘤能力。我们将重点关注TME中的缺氧、腺苷和离子失衡,以及癌细胞程序性细胞死亡配体1的过表达,这些因素要么抑制T细胞中的钾通道和/或受益于调节这些通道的活性,最终塑造免疫反应。最后,我们将回顾一些与离子通道相关的癌症治疗意义。更好地理解TME对T淋巴细胞中离子通道的影响可能会促进更有效的免疫疗法的发展,特别是对于耐药实体恶性肿瘤。